Nautilus Biotechnology, Inc.
NAUTHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Nautilus Biotechnology, Inc. (NAUT) is listed under Biotechnology. With a market capitalization of $411.7M, it sits in small-cap territory. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Market Cap
$411.7M
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-4.38
EPS (TTM)
$-0.45
EPS (Fwd)
$-0.74
ROE
-36.2%
ROA
-20.8%
Cash
$84.0M
Total Debt
$27.8M
Free CF
-$29.4M
52W Change
140.0%
Annual Financials
Cash vs Debt
Where NAUT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NAUT finished 30.20% above its 150-day moving average ($2.02) and 26.44% above its 200-day moving average ($2.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NAUT overbought or oversold?
At the October 20, 2026 close, NAUT's RSI(14) was 75.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nautilus Biotechnology, Inc. holds $84.0M in cash against $27.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$29.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -36.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NAUT.